{
    "clinical_study": {
        "@rank": "36774", 
        "acronym": "AMA", 
        "arm_group": {
            "arm_group_label": "Abiraterone Acetate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate antitumour activity of abiraterone acetate in\n      Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast\n      Cancer."
        }, 
        "brief_title": "Abiraterone Acetate in Molecular Apocrine Breast Cancer", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Screening : All women 18+, with a confirmed locally advanced or metastatic Triple Negative\n      Breast Cancer (TNBC), will be screened and invited to participate (300-500 patients).\n\n      Only patients with a centralized confirmation of ER-/PR-/HER2- and evaluation of AR+ will be\n      included and treated with abiraterone acetate plus prednisone (31 patients).\n\n      The Treatment phase comprises a series of 4 weeks-cycles with continuous study treatment.\n      Study drug treatment will continue until the earliest of the following events: disease\n      progression, unacceptable toxicity, or death.\n\n      At disease progression, patients must be discontinued from study drug and should be\n      evaluated within 30 days during the Post treatment visit and then entered into the Follow-Up\n      phase.Patients should enter the Follow-Up Period regardless of reason for study drug\n      discontinuation and should be monitored every 3 months (\u00b1 7 days) during 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged \u2265 18 years;\n\n          -  Histologically confirmed locally advanced or metastatic breast cancer;\n\n          -  Triple negative breast cancer:\n\n        Estrogen receptor (ER)-negative and Progesterone receptor (PR)-negative, as defined by a\n        < 10 % tumour stained cells by immunohistochemistry (IHC); HER2 negative status (i.e. IHC\n        score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), confirmed centrally before\n        inclusion with FFPE tissue from either primary or metastatic breast cancer site*;\n\n          -  Androgen receptor (AR)-positive, as defined centrally by a \u2265 10% tumour stained cells\n             by IHC (AR assessment by local pathologist before inclusion is not mandatory);\n\n          -  Patients could be chemotherapy na\u00efve (provided they are not presenting with\n             life-threatening metastasis) or have received any number of previous lines of\n             chemotherapy (providing their life expectancy is  \u2265 3 months);\n\n          -  Pre and post menopausal patients are eligible.\n\n          -  Measurable or  non measurable disease according to RECIST v1.1 criteria;\n\n          -  PS (ECOG) \u2264 2;\n\n          -  Normal haematological function: ANC \u2265 1,500/mm3; platelets count \u2265 100,000/mm3;\n             haemoglobin > 10 g/dl;\n\n          -  Normal hepatic function: total bilirubin \u2264 1.5 upper normal limit (UNL); ASAT and\n             ALAT \u2264 2.5 UNL (\u2264 5 UNL in the presence of liver metastases);\n\n          -  Creatinine clearance (MDRD formula) \u2265 50 mL/min OR creatinine \u2264 1.5 times ULN;\n\n          -  Normal kalemia (serum potassium \u2265 3.5 mM), natremia and magnesemia;\n\n          -  Systolic blood pressure (BP) < 160 mm Hg and diastolic BP < 95 mm Hg, as documented\n             on inclusion day (Hypertension at baseline assessment allowed provided it is\n             currently controlled under anti-hypertensive drugs);\n\n          -  Cardiac ejection fraction \u226550% measured by MUGA or ECHO done within 4 weeks before\n             inclusion;\n\n          -  If receiving a bisphosphonate or denosumab, dose must have been stable for at least 2\n             doses before inclusion;\n\n          -  Patient agreeing to use effective contraception during and for \u2265 6 months after\n             completion of study treatment;\n\n          -  Patient able to comply with the protocol;\n\n          -  Patient must have signed a written informed consent form prior to any study specific\n             procedures;\n\n          -  Patient must be affiliated to a Social Health Insurance.\n\n        Exclusion Criteria:\n\n          -  Male breast cancer;\n\n          -  HER2-positive status (positivity defined as IHC3+ and/or FISH amplification >2.2);\n\n          -  Other concurrent malignancies, except adequately treated cone-biopsied in situ\n             carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin;\n             patients who have undergone potentially curative therapy for a prior malignancy are\n             eligible provided there is no evidence of disease for \u2265 5 years and patient is deemed\n             to be at low risk for recurrence;\n\n          -  Active brain metastases or leptomeningeal disease; History of brain metastases\n             allowed provided lesions are stable for at least 3 months as documented by head CT\n             scan or MRI of the brain;\n\n          -  Non-malignant systemic disease, including active infection or concurrent serious\n             illness that would make the patient a high medical risk;\n\n          -  Significant cardiovascular disease, including any of the following:\n\n               1. NYHA class III-IV congestive heart failure;\n\n               2. Unstable angina pectoris or myocardial infarction within the past 6 months;\n\n               3. Severe valvular heart disease;\n\n               4. Ventricular arrhythmia requiring treatment.\n\n          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase\n             deficiency or glucose-galactose malabsorption should not be included;\n\n          -  Patients with known allergies, hypersensitivity or intolerance to abiraterone\n             acetate, prednisone, or their excipients;\n\n          -  Persistent toxicities \u2265 grade 2 from any cause, except chemotherapy-induced alopecia\n             and Grade 2 peripheral neuropathy;\n\n          -  Active or uncontrolled autoimmune disease requiring concurrent corticosteroid\n             therapy;\n\n          -  Any gastrointestinal disorder interfering with absorption of the study drug;\n\n          -  Difficulties with swallowing study capsules;\n\n          -  Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy,\n             chemotherapy (CT) within the last 3 weeks (2 weeks for oral or weekly CT ; 6 weeks\n             for nitrosoureas and mitomycin C), or other investigational agents ; Concurrent\n             palliative radiotherapy allowed;\n\n          -  Concurrent enrolment in another clinical trial in which investigational therapies are\n             administered;\n\n          -  Pregnant women, women who are likely to become pregnant or are breast-feeding;\n\n          -  Patients with any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule;\n             those conditions should be discussed with the patient before registration in the\n             trial;\n\n          -  Patients with history of non compliance to medical regimens or unwilling or unable to\n             comply with the protocol;\n\n          -  Individual deprived of liberty or placed under the authority of a tutor."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842321", 
            "org_study_id": "CADUSEIME02", 
            "secondary_id": [
                "2012-002525-29", 
                "UC-0140/1206"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Abiraterone Acetate", 
            "description": "Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.", 
            "intervention_name": "Abiraterone Acetate", 
            "intervention_type": "Drug", 
            "other_name": "ZYTIGA"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "locally advanced", 
            "metastatic", 
            "Breast Cancer", 
            "Molecular Apocrine", 
            "HER2-negative", 
            "Abiraterone acetate"
        ], 
        "lastchanged_date": "September 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Avignon", 
                        "country": "France"
                    }, 
                    "name": "Institut Sainte Catherine"
                }, 
                "investigator": {
                    "last_name": "Julien GRENIER", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France"
                    }, 
                    "name": "Chu - Hopital Jean Minjoz"
                }, 
                "investigator": {
                    "last_name": "Christian VILLANUEVA", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "Institut Bergonie"
                }, 
                "investigator": {
                    "last_name": "Herv\u00e9 BONNEFOI", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "Polyclinique Bordeaux Nord Aquitaine"
                }, 
                "investigator": {
                    "last_name": "Nadine DOHOLLOU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "Chu de Brest - H\u00f4pital Morvan"
                }, 
                "investigator": {
                    "last_name": "Brigitte LUCAS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "Centre Francois Baclesse"
                }, 
                "investigator": {
                    "last_name": "Christelle LEVY", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Contamine - Sur - Arve", 
                        "country": "France"
                    }, 
                    "name": "Ch Alpes Leman"
                }, 
                "investigator": {
                    "last_name": "Carol ALLIOT", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France"
                    }, 
                    "name": "Chu de Grenoble - Hopital Michallon"
                }, 
                "investigator": {
                    "last_name": "Mireille MOUSSEAU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Roche-sur-yon", 
                        "country": "France"
                    }, 
                    "name": "Chd de Vendee"
                }, 
                "investigator": {
                    "last_name": "V\u00e9ronique GIRRE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "Centre Oscar Lambret"
                }, 
                "investigator": {
                    "last_name": "Audrey MAILLIEZ", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "investigator": {
                    "last_name": "Olivier TREDAN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "Institut Paoli Calmettes"
                }, 
                "investigator": {
                    "last_name": "Anthony GONCALVES", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mont de Marsan", 
                        "country": "France"
                    }, 
                    "name": "Ch de Mont de Marsan"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me DAUBA", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orleans", 
                        "country": "France"
                    }, 
                    "name": "Chr D Orleans - Hopital La Source"
                }, 
                "investigator": {
                    "last_name": "Corina CORNILA-PREDA", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Institut Curie - H\u00f4pital Claudius Regaud"
                }, 
                "investigator": {
                    "last_name": "Paul COTTU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perpignan", 
                        "country": "France"
                    }, 
                    "name": "Ch de Perpignan"
                }, 
                "investigator": {
                    "last_name": "Fawzi KARA SLIMANE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France"
                    }, 
                    "name": "Ch Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "Benoit YOU", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pringy", 
                        "country": "France"
                    }, 
                    "name": "CH de la R\u00e9gion d'Annecy"
                }, 
                "investigator": {
                    "last_name": "Laetitia STEFANI", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "Institut Jean Godinot"
                }, 
                "investigator": {
                    "last_name": "Christelle JOUANNAUD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "investigator": {
                    "last_name": "Marianne LEHEURTEUR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-herblain", 
                        "country": "France"
                    }, 
                    "name": "Ico- Site Rene Gauducheau"
                }, 
                "investigator": {
                    "last_name": "Mario CAMPONE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "Centre Paul Strauss"
                }, 
                "investigator": {
                    "last_name": "Thierry PETIT", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "Hopital Civil - Strasbourg"
                }, 
                "investigator": {
                    "last_name": "Philippe BARTHELEMY", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thonon Les Bains", 
                        "country": "France"
                    }, 
                    "name": "Hopitaux Du Leman"
                }, 
                "investigator": {
                    "last_name": "Francesco DEL PIANO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "investigator": {
                    "last_name": "Florence DALENC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vannes", 
                        "country": "France"
                    }, 
                    "name": "Ch Bretagne Atlantique"
                }, 
                "investigator": {
                    "last_name": "Emmanuel BLOT", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "c-orsini@unicancer.fr", 
            "last_name": "Christine Orsini, PhD", 
            "phone": "+33 (0)1 71 93 67 07"
        }, 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9, Bordeaux", 
            "last_name": "Herv\u00e9 BONNEFOI, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The 6-months CBR is the measurement of all patients who have a complete response (CR), partial response (PR) or stable disease (SD), according to RECIST criteria v1.1. At six months, patients will be classified as success (Alive at 6 months AND CR/PR/ SD) or failure (dead OR alive with progression).", 
            "measure": "Clinical benefit rate (CBR)", 
            "safety_issue": "No", 
            "time_frame": "at 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Objective response is defined as complete response (CR) or partial response (PR) according to RECIST criteria v1.1", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months"
            }, 
            {
                "description": "The DoR is defined as the time from documentation of tumour response (CR/PR whichever is first recorded) to disease progression, according to RECIST criteria v1.1.", 
                "measure": "Duration of overall response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months"
            }, 
            {
                "description": "The OS is defined as the time from the first administration of abiraterone acetate to death from any cause.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "median follow-up =  2 years"
            }, 
            {
                "description": "The PFS is defined as the time from the first administration of abiraterone acetate to progression or death of any cause, whichever occurs first.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "median follow-up = 2 years"
            }, 
            {
                "description": "The overall safety profile of the treatment is determined by the occurrence of adverse events and toxicities. The severity of the adverse events and toxicities will be graded according the NCI CTCAE scale version 4.0.", 
                "measure": "Overall safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "during the on-treatment period (defined as the period from the time of first dose of study medications up to 30 days of the last dose)"
            }
        ], 
        "source": "UNICANCER", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}